Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC-4
- Development stage
- Preclinical
- Lead developer
- Sungkyunkwan University
- Modality
- Small Molecules
01
Overview
MC-4 is a partially purified material derived from the plant *Artemisia annua* L. (sweet wormwood) that is being investigated for its potential as an anticancer therapy, specifically for advanced renal cell carcinoma (RCC). It functions as a novel inhibitor of the Akt and pyruvate kinase muscle isozyme M2 (PKM2) pathways. By enhancing the expression of the tumor suppressor phosphatase and tensin homolog (PTEN), MC-4 reduces downstream Akt/PKM2 signaling, which in turn decreases the expression of glucose transporter 1 (GLUT1) and disrupts cancer cell metabolism. Preclinical research indicates that MC-4 monotherapy induces autophagic cell death and tumor growth inhibition. Furthermore, when used in combination with the mTORC1 inhibitor everolimus, MC-4 demonstrates synergistic antitumor and anti-metastatic effects by overcoming compensatory Akt activation typically induced by mTOR inhibition.
- Other names
- Artemisia annua L. extract
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)PKM2 (Pyruvate kinase M2 isoform)
Beyond the preview
Go deeper on MC-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC-4.